Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Safety of Nebulized Combination Therapy BromAc® in COVID-19 Respiratory Disease: a Phase 1 Study

NCT05258682 is registered in ClinicalTrials.gov with Mucpharm Pty Ltd as lead sponsor.

NCT NCT05258682
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05258682 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Safety of Nebulized Combination Therapy BromAc® in COVID-19 Respiratory Disease: a Phase 1 Study
Lead sponsor
Mucpharm Pty Ltd
Phase
Phase 1/2
Overall status
Unknown status
Start date
May 1, 2022
Completion date
October 30, 2022
Enrollment
30 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

covid-19, covid-19 acute respiratory distress syndrome, covid-19 pneumonia, ventilator associated pneumonia